News Alnylam hopes for 2018 filing for RNAi liver disease drug Alnylam is hoping to file a second RNA interference (RNAi) drug with the FDA by the end of 2018 after unveiling encouraging early-stage data for givosiran in a rare liver disease.<
News Novo Nordisk board member quits over NASH conflict of intere... Mary Szela has quit to avoid a conflict of interest.
News Can Gilead find another Pharmasset in 2017? Company needs to make acquisition to grow, admits CEO.
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
